Bicatero (Bicalutamide)

Bicatero (Bicalutamide) is a non-steroidal anti-androgen medication designed for the treatment of advanced and metastatic prostate cancer. This prescription pharmaceutical works by blocking androgens—male hormones such as testosterone—at the receptor level, preventing these hormones from stimulating the growth of prostate cancer cells. Bicalutamide is frequently prescribed alongside gonadotropin-releasing hormone (GnRH) analogues for medical castration or following surgical castration to provide comprehensive hormonal therapy in prostate cancer management.

As a potent anti-androgen agent, Bicatero is indicated primarily for patients with hormone-sensitive prostate cancer who require androgen deprivation therapy. The medication may also be used off-label in conditions involving androgen excess under appropriate medical supervision. Its mechanism of action makes it a cornerstone treatment in oncology protocols for managing advanced malignancies of the prostate gland.

Bicatero is contraindicated in patients with hypersensitivity to bicalutamide or any component of the formulation, in women and children (as it is not approved for these populations), and in those with severe hepatic impairment due to increased toxicity risk. Concurrent use with certain medications such as cisapride, terfenadine, and astemizole is contraindicated due to serious drug interaction potential.

Dosage and administration of Bicatero must be determined by your healthcare provider based on individual clinical assessment, disease stage, and overall health status. This medication requires medical consultation and should not be taken without explicit direction from a qualified physician. Always follow your doctor's prescribed dosage and prec